UTHR vs. CTLT

In the year-to-date period, UTHR achieves a 63.53% return, which is significantly higher than CTLT's 41.29% return. Over the past 10 years, UTHR has outperformed CTLT with an annualized return of 10.72%, while CTLT has yielded a comparatively lower 8.89% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and Catalent, Inc. (CTLT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current UTHR Sharpe Ratio is 2.10, which is comparable to the CTLT Sharpe Ratio of 2.58. The chart below compares the historical Sharpe Ratios of UTHR and CTLT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither UTHR nor CTLT has paid dividends to shareholders.

The maximum UTHR drawdown since its inception was -93.18%, which is greater than CTLT's maximum drawdown of -77.62%. Use the drawdown chart below to compare losses from any high point for UTHR and CTLT. For additional features, visit the drawdowns tool.

United Therapeutics Corporation (UTHR) has a higher volatility of 8.49% compared to Catalent, Inc. (CTLT) at 3.16%. This indicates that UTHR's price experiences larger fluctuations and is considered to be riskier than CTLT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between United Therapeutics Corporation and Catalent, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.